Price
$322.10+65.39%Social Signal Score
Analyst Ratings
28 analystsRevenue
$793.98M+1510.54%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Solomon Moshkevich
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 6,138
- Beta
- 1.51
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 26.83
Financials
Revenue
$793.98M+1510.5%Net Income
$-59.91MEBITDA
$-36.74MFree Cash Flow
$5.25MEPS (diluted)
$-0.42Shares Outstanding (diluted)
144.07M+173.1%Operating Expenses
$576.09MCash & Debt
$1.10BRevenue by Segment (annual)
$2.31BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.31B | $-208.16M | $-1.52 |
| 2024 | $1.70B | $-190.43M | $-1.53 |
| 2023 | $1.08B | $-434.80M | $-3.78 |
| 2022 | $820.22M | $-547.80M | $-5.57 |
| 2021 | $625.49M | $-471.72M | $-5.21 |
| 2020 | $391.00M | $-229.74M | $-2.84 |
| 2019 | $302.33M | $-124.83M | $-1.79 |
| 2018 | $257.65M | $-128.15M | $-2.22 |
| 2017 | $210.94M | $-136.31M | $-2.56 |
| 2016 | $217.07M | $-95.77M | $-1.86 |
| 2015 | $190.35M | $-70.28M | $-1.47 |
| 2014 | $159.29M | $-5.15M | $-0.14 |
| 2013 | $55.17M | $-37.11M | $-1.01 |
| 2012 | $14.25M | $-76.17M | $-24.37 |
Valuation
NTRAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-37.50%Social Signal Score
Mentions (51)
- News (RSS)investing·2d ago·Neutral
AI Takes On Cancer Detection From a Single Blood Draw (MEDS, ANT, GH, GRAL, NTRA, FRNM)
View source ↗ - News (RSS)fool·3d ago·Positive
Natera vs. Tempus AI: Which Blood Test Pioneer Has the Better Stock Buy for 2027? Natera's revenue growth tops 37%, but Tempus AI trades at a lower forward multiple, and the balance sheets and cash flow stories diverge sharply.
View source ↗ - Newsfool.com·3d ago·Positive
Natera vs. Tempus AI: Which Blood Test Pioneer Has the Better Stock Buy for 2027? Natera dominates the molecular diagnostics market with high revenue growth and positive free cash flow. Tempus AI leverages a massive multimodal data library and artificial intelligence to drive precision medicine.
View source ↗ - Newsmarketbeat.com·7d ago·Positive
Natera CFO Maps Multiple Paths to $6 Billion Revenue Target by 2029 Natera NASDAQ: NTRA Chief Financial Officer Mike Brophy said the company has multiple paths to its $6 billion revenue target for 2029, citing growth in its Signatera cancer testing business and opportunities to improve reimbursement.
View source ↗ - News (RSS)seekingalpha·11d ago·Positive
Natera, Inc. (NTRA) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·11d ago·Positive
Natera, Inc. (NTRA) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript Natera, Inc. ( NTRA ) 8th Annual Wolfe Research Healthcare Conference November 10, 2026 12:00 PM EST Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Paige Chamberlain - Wolfe Research, LLC Presentation Paige Chamberlain Wolfe Research, LLC Hi, everyone. Thanks for being here.
View source ↗ - Newszacks.com·13d ago·Positive
Natera Q3 Earnings Call Highlights $6B Target & Raised 2026 Outlook NTRA targets $6B in revenues by 2029 as Signatera testing surges, reimbursement expands and higher investments support its long-term growth strategy.
View source ↗ - Newszacks.com·13d ago·Neutral
NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View Up Natera???s Q3 revenues jump 34.1%, beating estimates, while a wider-than-expected loss and surging oncology test volumes shape its raised 2026 sales outlook.
View source ↗ - News (RSS)seekingalpha·15d ago·Positive
Natera, Inc. (NTRA) Q3 2026 Earnings Call Transcript
View source ↗ - News (Marketaux)seekingalpha.com·15d ago·Neutral
Natera, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:NTRA) 2026-11-07 Natera, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:NTRA) 2026-11-07
View source ↗ - News (RSS)seekingalpha·15d ago·Neutral
Natera, Inc. 2026 Q3 - Results - Earnings Call Presentation
View source ↗ - Newsseekingalpha.com·15d ago·Positive
Natera, Inc. (NTRA) Q3 2026 Earnings Call Transcript Natera, Inc. ( NTRA ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - CEO & Director Solomon Moshkevich - President of Clinical Diagnostics Alexey Aleshin - GM of Oncology and Early Cancer Detection & Chief Medical Officer Conference Call Participants Daniel Brennan - TD Cowen, Research Division Puneet Souda - Leerink Partners LLC, Research Division Daniel Markowitz …
View source ↗ - News (RSS)investing·15d ago·Neutral
Cathie Wood’s ARK sells CareDx stock, buys Natera and Kratos
View source ↗ - News (RSS)zerohedge·16d ago·Neutral
…its revenue growth guidance for the full year.Monster Beverage (MNST) slides 6% as the energy drink distributor reported a miss on third-quarter gross margin.Natera (NTRA) sinks 14% after the cancer test maker said CEO Steve Chapman was stepping down effectively immediately and succeeded by Solomon Moshkevich. Analysts view the CEO change as a surprise that overshadows the firm’s third-quarter results.Under Armour (UAA) falls 13% after the athletic apparel and footwear company reduced its year g…
View source ↗ - Newsmarketbeat.com·16d ago·Neutral
What Natera (NTRA) Said on Its Q3 Earnings Call Natera NASDAQ: NTRA raised its full-year revenue forecast after reporting a 34% increase in third-quarter revenue, as demand for its cancer-monitoring tests grew and the company announced a change in leadership.
View source ↗ - News (RSS)seekingalpha·17d ago·Neutral
Natera GAAP EPS of -$0.42 misses by $0.15, revenue of $794M beats by $86.5M
View source ↗ - Newsbenzinga.com·23d ago·Neutral
Natera, Shake Shack, eBay And More On CNBC's ‘Final Trades' On CNBC's “Halftime Report Final Trades,” Rob Sechan, founder and managing partner of NewEdge Capital Group, picked eBay Inc. (NASDAQ:EBAY).
View source ↗ - Newszacks.com·25d ago·Neutral
NTRA Q3 Earnings on Deck: Will Signatera Volume Growth Drive Results? Natera's third-quarter 2026 results hinge on Signatera volume growth, regulatory milestones and higher test prices, while expanding Medicare coverage may boost organ health revenues.
View source ↗ - Newsbusinesswire.com·27d ago·Neutral
…d Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™ AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the American Society of Nephrology (ASN) Kidney Week 2026, highlighting the unique value genetic testing can provide for patients with CKD. These 18 abstracts, including three oral presentations, add to the growing…
View source ↗ - Newsfool.com·28d ago·Neutral
Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree. Druckenmiller owns a large stake in Natera. The company is growing quickly by disrupting the healthcare testing market.
View source ↗ - Newszacks.com·32d ago·Neutral
Natera Partners With TransCode to Advance Colorectal Cancer Trial NTRA partners with TransCode Therapeutics to use Signatera MRD testing in a Phase 2a colorectal cancer trial, aiming to accelerate enrollment and research.
View source ↗ - Newsbusinesswire.com·35d ago·Neutral
…ations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD Technology AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, taking place October 23–26 in Madrid, Spain.New evidence highlights the power of Natera's latest ultrasensitive molecul…
View source ↗ - Newsfxempire.com·38d ago·Positive
Natera (NTRA) Price Forecast: Bullish Trend Holds as Next Leg Looms Natera shares consolidate after a 76% rally, holding key moving-average support as traders watch for a breakout above $437.41 to extend the bullish trend.
View source ↗ - Newsbusinesswire.com·38d ago·Positive
Natera's Signatera™ MRD Test Named to TIME's List of the Best Inventions of 2026 AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has been named to TIME's Best Inventions of 2026 list, featuring extraordinary innovations that are changing lives.TIME's Best Inventions list, published annually, highlights the technologies and breakthroughs making the world b…
View source ↗ - Newszacks.com·38d ago·Positive
Natera Gains 118.1% in a Year: What's Driving the Rally? NTRA shares surge 118.1% in a year, fueled by robust Signatera adoption, expanding test volumes and improving margins, despite competition and rising costs.
View source ↗ - News (RSS)investing·40d ago·Neutral
Natera partners with TransCode for cancer trial enrollment
View source ↗ - News (RSS)seekingalpha·46d ago·Neutral
Natera: Priced To Perfection Amidst Rising Competitive Threats
View source ↗ - News (Marketaux)gurufocus.com·48d ago·Positive
Natera Inc (NTRA) Shares Surge 3.7% -- What GF Score of 71 Tells Investors On October 05, 2026, Natera <em[+228 characters]
View source ↗ - Newsbenzinga.com·55d ago·Neutral
Natera, UnitedHealth Group And A Tech Stock On CNBC's ‘Final Trades' On CNBC's “Halftime Report Final Trades,” Rob Sechan, CEO of NewEdge Wealth, picked Hewlett Packard Enterprise Company (NYSE:HPE).
View source ↗ - Newszacks.com·60d ago·Neutral
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx NTRA wins Japan PMDA approval for Signatera in muscle-invasive bladder cancer, supporting treatment decisions and a planned 2027 commercial launch.
View source ↗ - News (Marketaux)gurufocus.com·61d ago·Positive
A Look at Natera Inc (NTRA) After 5.5% Gain -- GF Value $219.69 vs Price $390.90 On September 22, 2026, Natera <[+249 characters]
View source ↗ - News (RSS)investing·61d ago·Neutral
Natera Inc stock reaches all-time high at 373.58 USD
View source ↗ - Newsseekingalpha.com·62d ago·Positive
Natera, Inc. (NTRA) Presents at 2026 Global Healthcare Conference Transcript Natera, Inc. (NTRA) Presents at 2026 Global Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·63d ago·Positive
Natera, Inc. (NTRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·63d ago·Positive
Natera, Inc. (NTRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Natera, Inc. (NTRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (Marketaux)rttnews.com·65d ago·Positive
Show Me The Money: Natera Delivers Over 120% Gain In Just About A Year For Natera Inc. (NTRA)[+266 characters]
View source ↗ - Newsbusinesswire.com·65d ago·Neutral
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea. Natera and its collaborators presented four abstracts, including two oral presentations. A mini-oral presentation featured the largest molecular residual disease (MR…
View source ↗ - Newsbusinesswire.com·82d ago·Neutral
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly diagnosed and relapsed/refractory (R/R) lymphoma. PET/CT scans serve as the standard tool for assessing treatment response in lymp…
View source ↗ - News (RSS)yahoo·85d ago·Positive
Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run?
View source ↗ - News (RSS)fool·85d ago·Positive
Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run? The billionaire has good reasons to like this genetic testing leader.
View source ↗ - Newsfool.com·85d ago·Positive
Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run? The billionaire has good reasons to like this genetic testing leader.
View source ↗ - Newsbusinesswire.com·86d ago·Positive
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen®, the world's leading breast cancer organization. Together, the organizations aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera's SignateraTM MRD t…
View source ↗ - News (Marketaux)finance.yahoo.com·90d ago·Positive
Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either. It was a genetic testing company called [+275 characters]
View source ↗ - News (Marketaux)seekingalpha.com·94d ago·Positive
Natera: Even 30% Annual Growth Through 2030 Doesn't Support $310 Per Share (NASDAQ:NTRA) Natera ( NTRA ) had a fantastic[+263 characters]
View source ↗ - Newszacks.com·97d ago·Neutral
Natera Supports Kupando Trial to Advance ctDNA Monitoring in Cancer NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and characterize response to KUP-101.
View source ↗ - Newsmarketbeat.com·99d ago·Negative
Natera Spotlights Record Signatera Volumes, Raises Outlook at Canaccord Conference Natera NASDAQ: NTRA Chief Financial Officer Mike Brophy said the company delivered strong second-quarter momentum across its women's health, oncology and organ health businesses, citing record Signatera volumes, continued revenue and average selling price strength, improved gross margins and narrowing losses while maintaining elevated investment levels.
View source ↗ - Newsseekingalpha.com·101d ago·Positive
Natera, Inc. (NTRA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript Natera, Inc. (NTRA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
View source ↗ - News (RSS)investing·102d ago·Neutral
Natera partners with Kupando for phase 1 cancer trial in Germany
View source ↗ - Newsbusinesswire.com·102d ago·Negative
Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration regarding a Phase 1 clinical trial, sponsored by Kupando Therapeutics. Under the agreement, Natera's Latitude tissue-free assay for molecular residual disease (MRD) detection will be used in Kupando's clinical trial of its lead immunotherapy ca
View source ↗ - Newsfool.com·106d ago·Positive
Stanley Druckenmiller's Portfolio Skips Megacap Tech Almost Entirely. Here's What He's Buying Instead. Druckenmiller only owns one "Magnificent Seven" stock.
View source ↗ - Newsforbes.com·107d ago·Negative
Natera Shares Soar Over 20% To All-Time High, Bolstering Co-Founder's Billionaire Status 40.6%. That is how much Natera shares have grown since the start of the year, when they were priced around the $228 mark. The company's lowest closing price this year occurred in late March, when shares fell to $182.65.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-0.16 per share
Typical surprise -3.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.42 vs $-0.28miss
- Thu, Aug 6$-0.47 vs $-0.49beat
- Thu, May 7$-0.56 vs $-0.54miss
- Thu, Feb 26$0.35 vs $-0.51beat
- Thu, Nov 6$-0.64 vs $-0.39miss
- Thu, Aug 7$-0.74 vs $-0.62miss
Estimates and results for NTRA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NTRA officers and directors.
- Bought
- —
- Sold
- $15.8m
0 trades
99 trades
- Sheena Jonathansold
- Sheena Jonathansold
- Sheena Jonathansold
- Sheena Jonathansold
- Sheena Jonathansold
- Sheena Jonathansold
- Sheena Jonathansold
- Sheena Jonathansold
1 further Form 4 entry is share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Josh Gottheimerhouse · NJ05 · disclosed Oct 16, 2025 (24d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Sep 8, 2025 (17d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Aug 12, 2025 (21d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Dec 6, 2024 (16d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed May 19, 2023 (39d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (42d later)Buy$1,001 - $15,000
- William Francis Hagertysenate · TN · disclosed May 4, 2021 (14d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
